TrialClinical pharmacology in drug development2024

New Ustekinumab Biosimilar Candidate FYB202: Pharmacokinetic Equivalence Demonstrated in a Randomized, Double-Blind, Parallel-Group, Single-Dose Trial in Healthy Subjects.

Sigrid Balser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.